Bioequivalence study of Eplerenone 50mg tablet of Alborzdarou Pharm Co., IRAN

A randomized, open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Eplerenone 50mg tablet of Alborzdarou Pharm. Co.., IRAN in comparison of Inspra 50mg tablet of Pfizer in 24 healthy human adult subjects under fasting condition

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190706044111N11

Enrollment

Registered

2019-10-09

Start date

2019-11-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension. Hypertensive heart disease with (congestive) heart failure

Interventions

Intervention 1: Intervention group: Single dose of Eplerenon 50mg tablet of Alborzdarou Pharm Co., IRAN. Intervention 2: Control group: Single dose of Inspra 50mg tablet of Pfizer.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: - Aged between 18 - 50 years - Body weight between 50 – 100 kg - Having good health on the basis of medical history and physical & clinical examination - Understand the procedures and give written informed consent

Exclusion criteria

Exclusion criteria: Subject showed clinically relevant deviations from normal in physical examination. Subject had undergone surgery of the gastro-intestinal tract Subject had donated a unit of blood or participated in another clinical trial, within the last three months before the first treatment. Subject had a history of drug or alcohol abuse. Subject who smokes more than 10 cigarettes per day. Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment. Subject had a history of allergic to drug

Design outcomes

Primary

Measure	Time frame
Plasma concentration of eplerenone. Timepoint: At 0 (before dosing), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 & 24.0 hr. after drug administration. Method of measurement: High Performance Liquid Chromatography (HPLC).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLadan Tayebi

Pars Biopharmacy Research Co.

l.tayebi@parsbiopharmacy.com+98 21 8895 6061

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026